Deka Biosciences, Inc Email Format

Biotechnology ResearchMaryland, United States11-50 Employees

Deka Biosciences, Inc. is an early-stage biotechnology company focused on developing targeted cytokine therapies for cancer and inflammatory diseases. It is advancing a dual cytokine platform called Diakine, which combines optimized IL-10 variants with other cytokines through tissue-targeting, long-half-life scFv technology that is non-immunogenic. The platform aims to provide disease-specific immune modulation by linking IL-10 variants to complementary cytokines.

Based in Germantown, Maryland, the company operates within the biotechnology research sector as it advances its early-stage programs. In December 2023, Deka announced the appointment of senior clinical leadership and board oversight, including Stanley Frankel as senior clinical advisor and interim chief medical officer, and Stuart Chaffee as an independent director and chairman of the board.

Sign up for free to view info

Company overview Employee directory